作者
Lars Køber, Jens J Thune, Jens C Nielsen, Jens Haarbo, Lars Videbæk, Eva Korup, Gunnar Jensen, Per Hildebrandt, Flemming H Steffensen, Niels E Bruun, Hans Eiskjær, Axel Brandes, Anna M Thøgersen, Finn Gustafsson, Kenneth Egstrup, Regitze Videbæk, Christian Hassager, Jesper H Svendsen, Dan E Høfsten, Christian Torp-Pedersen, Steen Pehrson
发表日期
2016/9/29
期刊
New England Journal of Medicine
卷号
375
期号
13
页码范围
1221-1230
出版商
Massachusetts Medical Society
简介
Background
The benefit of an implantable cardioverter–defibrillator (ICD) in patients with symptomatic systolic heart failure caused by coronary artery disease has been well documented. However, the evidence for a benefit of prophylactic ICDs in patients with systolic heart failure that is not due to coronary artery disease has been based primarily on subgroup analyses. The management of heart failure has improved since the landmark ICD trials, and many patients now receive cardiac resynchronization therapy (CRT).
Methods
In a randomized, controlled trial, 556 patients with symptomatic systolic heart failure (left ventricular ejection fraction, ≤35%) not caused by coronary artery disease were assigned to receive an ICD, and 560 patients were assigned to receive usual clinical care (control group). In both groups, 58% of the patients received CRT. The primary outcome of the trial was death from any cause. The …
学术搜索中的文章
L Køber, JJ Thune, JC Nielsen, J Haarbo, L Videbæk… - New England Journal of Medicine, 2016
